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Primary Alcohol-Activated Human 
and Mouse Hepatic Stellate Cells Share 
Similarities in Gene-Expression Profiles
Xiao Liu ,1,2* Sara Brin Rosenthal,3* Nairika Meshgin,1,2 Jacopo Baglieri,1,2 Sami G. Musallam,1 Karin Diggle,2 Kevin Lam,2 
Raymond Wu,4,5 Stephanie Q. Pan,4,5 Yibu Chen,6 Ken Dorko,7 Sharon Presnell,7 Chris Benner,2 Mojgan Hosseini,8  
Hidekazu Tsukamoto,4,5,9 David Brenner,2,4 and Tatiana Kisseleva1,4
Alcoholic liver disease (ALD) is a leading cause of cirrhosis in the United States, which is characterized by extensive 
deposition of extracellular matrix proteins and formation of a fibrous scar. Hepatic stellate cells (HSCs) are the major 
source of collagen type 1 producing myofibroblasts in ALD fibrosis. However, the mechanism of alcohol-induced ac-
tivation of human and mouse HSCs is not fully understood. We compared the gene-expression profiles of primary 
cultured human HSCs (hHSCs) isolated from patients with ALD (n  =  3) or without underlying liver disease (n  =  4) 
using RNA-sequencing analysis. Furthermore, the gene-expression profile of ALD hHSCs was compared with that 
of alcohol-activated mHSCs (isolated from intragastric alcohol-fed mice) or CCl4-activated mouse HSCs (mHSCs). 
Comparative transcriptome analysis revealed that ALD hHSCs, in addition to alcohol-activated and CCl4-activated 
mHSCs, share the expression of common HSC activation (Col1a1 [collagen type I alpha 1 chain], Acta1 [actin alpha 1, 
skeletal muscle], PAI1 [plasminogen activator inhibitor-1], TIMP1 [tissue inhibitor of metalloproteinase 1], and LOXL2 
[lysyl oxidase homolog 2]), indicating that a common mechanism underlies the activation of human and mouse HSCs. 
Furthermore, alcohol-activated mHSCs most closely recapitulate the gene-expression profile of ALD hHSCs. We iden-
tified the genes that are similarly and uniquely up-regulated in primary cultured alcohol-activated hHSCs and freshly 
isolated mHSCs, which include CSF1R (macrophage colony-stimulating factor 1 receptor), PLEK (pleckstrin), LAPTM5 
(lysosmal-associated transmembrane protein 5), CD74 (class I transactivator, the invariant chain), CD53, MMP9 (ma-
trix metallopeptidase 9), CD14, CTSS (cathepsin S), TYROBP (TYRO protein tyrosine kinase-binding protein), and 
ITGB2 (integrin beta-2), and other genes (compared with CCl4-activated mHSCs). Conclusion: We identified genes in 
alcohol-activated mHSCs from intragastric alcohol-fed mice that are largely consistent with the gene-expression profile 
of primary cultured hHSCs from patients with ALD. These genes are unique to alcohol-induced HSC activation in 
two species, and therefore may become targets or readout for antifibrotic therapy in experimental models of ALD. 
(Hepatology Communications 2020;4:606-626).
Alcoholic liver disease (ALD) progresses from hepatic steatosis to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma.(1) The incidence of ALD is on the rise. In the United States, ALD often occurs in patients with a body mass index (BMI) higher than 25-27(2) with nonalcoholic 
Abbreviations: ADA2, adenosine deaminase 2; aHSC, activated HSC; APF, anti-perinuclear factor; BMI, body mass index; CAV1, caveolin 1; 
CD74, class I transactivator, the invariant chain; COL1A1, collagen type I alpha 1 chain; CSF1R, macrophage colony-stimulating factor 1 receptor; 
CTSS, cathepsin S; CYBA, cytochromeb-245 light chain; CYP2E1, cytochrome P450 family 2 subfamily E member 1; DES, desmin; EMILIN, 
elastin microf ibril interface; GFAP, glial f ibrillary acidic protein; hHSC, human HSC; HSC, hepatic stellate cell; IG, intragastric; IGFBP3, insulin-
like growth factor binding protein 3; IL-6, interleukin-6; ITGB2, integrin beta-2; LAPTM5, lysosmal-associated transmembrane protein 5; LOX, 
lysyl oxidase; LRAT, lecithin retinol acyltransferase; mHSC, mouse HSC; MMP9, matrix metallopeptidase 9; mRNA, messenger RNA; NASH, 
nonalcoholic steatohepatitis; NTAM, neurotrimin; PAI1, plasminogen activator inhibitor-1; PLEK, pleckstrin; qHSC, quiescent HSC; RNA-Seq, 
RNA-sequencing; Spp1, secreted phosphoprotein 1; TGFβ1, transforming growth factor beta; Timp1, tissue inhibitor of metalloproteinase 1; TLR, 
toll-like receptor; TREM2, triggering receptor expressed on myeloid cells 2; TYROBP, TYRO protein tyrosine kinase-binding protein; α-SMA, 
a-smooth muscle actin.
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steatohepatitis (NASH), and can synergistically 
facilitate the development of liver fibrosis/cirrhosis. 
Therefore, new strategies for treatment of patients 
with ALD are urgently needed. The limited prog-
ress in treatment of alcoholic steatohepatitis and liver 
fibrosis in patients with ALD can be attributed, at 
least in part, to the lack of studies on primary healthy 
and alcohol-injured human hepatic stellate cells 
(hHSCs),(3) primarily due to challenges with hHSC 
isolation. Therefore, hHSC-derived immortalized cell 
lines are used widely to study hHSC biology, but do 
not fully recapitulate hHSC functions.
Hepatic stellate cells (HSCs) are the major source 
of fibrogenic myofibroblasts in alcohol-damaged liver. 
Under physiological conditions, HSCs exhibit a quies-
cent phenotype (qHSC), reside in the space of Disse, 
store vitamin A in lipid droplets, and function as liver 
pericytes.(1) In response to chronic alcoholic injury, 
HSCs lose vitamin A storage, and down-regulate the 
expression of quiescence-associated genes (PPARγ [per-
oxisome proliferator-activated receptor gamma], GFAP 
[glial fibrillary acidic protein], NGFR1 [nerve growth 
factor receptor], LRAT [lecithin retinol acyltrans-
ferase], CYGB [cytoglobin], and others), up-regulate 
the expression of fibrogenic genes (α-SMA [α-smooth 
muscle actin], FN1 [fibronectin], LOX [lysyl oxidase], 
Spp1 [secreted phosphoprotein 1]), and activate into 
collagen type 1–expressing myofibroblasts/activated 
HSCs (aHSCs).(4) Other cellular populations, such 
as activated portal fibroblasts (CD34+ Thy-1+ APFs 
[anti-perinuclear factors]) and fibrocytes (CD45+ 
CD34+ bone marrow–derived cells), were also shown 
to contribute to a small fraction of hepatic myofibro-
blasts in alcohol-injured liver.(4)
The characteristics of qHSCs and aHSCs (versus 
APFs and fibrocytes) were determined based on the 
gene-expression profiling of mouse HSCs (mHSCs) 
activated in response to experimental models of toxic 
liver injury in mice, such as CCl4, a hepatotoxin that 
causes hepatocyte apoptosis without changing their 
metabolic properties, or the intragastric (IG) model of 
alcohol infusion, which causes hepatotoxic and meta-
bolic damage of hepatocytes.(5) Similar to patients with 
ALD (and specifically patients with ALD with NASH), 
IG alcohol-fed mice develop steatosis, steatohepatitis, 
and liver fibrosis. Mice fed ad libitum alcohol-containing 
Western liquid diet with weekly alcohol binge develop 
milder liver fibrosis, and the transcriptome of aHSCs/
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myofibroblasts isolated from this model has recently 
been examined in relation to epigenetic regulation.(6) 
Although aHSCs were implicated in the fibrogenesis of 
both CCl4 and alcohol-induced liver fibrosis, it remains 
unknown whether alcohol can uniquely activate HSCs 
in mouse models of ALD and in patients. In fact, no 
studies have been conducted to assess the comparative 
gene-expression profile of alcohol-activated hHSCs 
and mHSCs (vs. CCl4-injured mHSCs).
Here, we isolated and characterized primary cultured 
hHSCs (from donor livers declined for transplantation) 
using RNA-sequencing (RNA-Seq) and quantitative 
real-time PCR. Normal hHSCs were isolated from 
donor livers with no history of liver disease and were 
compared with ALD hHSCs (from donors with alcohol- 
induced liver fibrosis). The comparative analysis of 
alcohol-activated hHSCs and mHSCs identified that a 
common mechanism underlying activation of hHSCs 
and mHSCs, such as expression of fibrogenic markers 
(Col4a1 [collagen type IV alpha 1 chain], Col1a1 [col-
lagen type I alpha 1 chain], TIMP1 [tissue inhibitor of 
metalloproteinase 1], Lox, PDGFRβ [platelet-derived 
growth factor receptor-beta]), was universally induced in 
both. We also identified a unique set of genes (CSF1R 
[macrophage colony-stimulating factor 1 receptor], 
PLEK [pleckstrin], LAPTM5 [lysosmal-associated 
transmembrane protein 5], CD74 [class I transactivator, 
the invariant chain], CD53, MMP9 [matrix metallopep-
tidase 9], CD14, CTSS [cathepsin S], TYROBP [TYRO 
protein tyrosine kinase-binding protein], and ITGB2 
[integrin beta-2]) that is uniquely up-regulated in both 
alcohol-activated mHSCs and hHSCs (but not by 
CCl4). These genes may serve as targets for antifibrotic 
therapy in ALD, but the physiological role of these 
genes in preclinical models of patients with alcohol- 
induced liver fibrosis and ALD remains to be determined. 
Alternatively, translating our findings in humans to mice, 
down-regulation of these genes in mHSCs might serve 
as a readout of successful treatment of alcohol-induced 
liver fibrosis in experimental models of ALD.
Materials and Methods
isolation oF alD anD noRmal 
Human HsCs
Livers declined for transplantation (internal review 
board 171883XX, approved on November 9, 2017, in 
collaboration with the Lifesharing [www.lifes haring.
org; San Diego, CA] organ procurement organiza-
tion [OPO]), were graded for steatosis, inflammation, 
and fibrosis by a pathologist using a double-blinded 
method,(7) and identified as ALD or normal. Primary 
hHSCs were purified from livers using pronase/
collagenase perfusion and gradient centrifugation 
method,(8) cultured for 3  weeks (P0), passaged once 
(P1) or twice (P2), and analyzed by immunocyto-
chemistry and quantitative real-time PCR.
isolation oF mouse HsCs
Col1a1YFP mice (male, C57BL6, 12  weeks old) 
were generated by crossing Col1a1Cre  ×  Rosa26f/f-YFP 
mice and were subjected to CCl4-induced liver fibro-
sis (1:4 in corn oil, 200 μL, 12 times over 6  weeks, 
oral gavage, n  =  6) or corn oil (control). Col1a1GFP 
transgenic mice(9) were subjected to alcoholic hepati-
tis and fibrosis by hybrid feeding ad libidum of a diet 
high in cholesterol and saturated fat, and IG feeding 
of alcohol liquid diet plus weekly alcohol binge (IG 
alcohol-fed mice). See Supporting Information for 
details.
immunoHistoCHemistRy
Human livers (formalin-fixed, paraffin-embedded) 
were stained with the anti-CD68 (ab955; Abcam, 
Cambridge, United Kingdom), anti-α-SMA (ab5694, 
Abcam), and anti-DES (desmin; Rb-9014-P0; 
Thermo Fisher Scientific, Waltham, MA) Abs. See 
Supporting Information for details.
Rna-seq analysis
RNA-Seq analysis of alcohol-activated hHSCs and 
mHSCs. Strand-specific messenger RNA (mRNA)- 
sequencing libraries (polyA+) were generated using 
Illumina TruSeq stranded mRNA library prep kits (San 
Diego, CA) and sequenced on an Illumina HiSeq2500 
to a depth of approximately 25 million reads. See 
Supporting Information for details.
FunCtional enRiCHment 
analysis
Functional enrichment analysis was conducted 
using the ToppGene suite(10) on the top 500 most 
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differ entially expressed genes identified in alcohol- 
activated (vs. normal) hHSCs, alcohol-activated (vs. 
quiescent) mHSCs, and CCl4-activated (vs. quiescent) 
mHSCs.
patHWay analysis
Pathway analysis was conducted using the Top-
pGene suite, which contains a collection of pathways 
from various sources. The pathways from KEGG 
and REACTOME, along with some other smaller 
databases of pathways (including BIOCARTA and 
the pathway interaction database) are used as the 
collection of gene sets to enrich against. Essentially, 
the ToppGene collection of pathways contains the 
union of pathways from each database. The P value 
was corrected for the total number of pathways in the 
database.
netWoRK analysis
Thirty-five genes that were commonly dysregulated 
in alcohol-activated hHSCs/mHSCs were integrated 
with the STRING protein–protein interaction net-
work using the STRING web interface, with all edges 
of medium or high confidence (https ://string-db.
org).(11) This network was further pruned to a highly 
connected core set of genes by taking the subset of 
genes with two or more connections to form the ALD 
signature gene set.
statistiCal analyses
Statistical analyses were conducted using the R 
project for statistical computing (https ://www.r-proje 
ct.org/) and python (https ://www.python.org/). See 
Supporting Information for details.
Results
CHaRaCteRiZation oF alD 
liVeRs VeRsus noRmal liVeRs
Non-transplanted donor livers were obtained 
through collaboration with the Lifesharing OPO. A 
liver pathologist assessed the histology in a double- 
blinded manner. Donors with no underlying liver dis-
ease (n = 4, average age = 43 years, BMI = 27.8) were 
considered as normal. Donors with ALD (n = 3, aver-
age age = 49 years, BMI = 30.8) were identified based 
on patient history (excessive alcohol consumption >   
5 drinks daily), liver function, steatosis grade (1-3, 
hematoxylin and eosin [H&E]), lobular inflammation 
score (scale 0-3), and fibrosis stage (n  =  2, stage 2; 
n = 1, stage 4; scale 0-4, Brunt-Keiner methodology, 
Fig. 1A). Specifically, ALD was diagnosed based on 
elevated serum aspartate aminotransferase (average 225 
vs. normal 37), increased fibrosis (positive area of sirius 
red staining: 13.2% ± 1.5% vs. normal 1.5% ± 0.1%), 
activation of α-SMA+ aHSCs/myofibroblasts (posi-
tive area 26.7% ± 3.1% vs. normal 11.9% ± 1%), and 
CD68+ myeloid cells (positive area, 4.4%  ±  0.5% 
vs. normal 2.9% ± 0.1%, Fig. 1B).
HigH puRity oF pRimaRy hHsC 
CultuRes Was aCHieVeD
Human HSCs were isolated from normal or 
ALD livers. Normal hHSCs (n  =  4) and alcohol- 
activated hHSCs (n = 3) were cultured for more than 
3  weeks and characterized. Both alcohol-activated 
hHSCs and normal hHSCs exhibited stellate shape 
and expressed HSC-specific markers (number of 
GFAP+ stained cells = 95% ± 3%; DES = 85% ± 5%; 
Fig. 1C), and lacked expression of albumin (marker 
of hepatocytes), CD45 (bone marrow–derived cells), 
CD11b (myeloid cells), PECAM1 (platelet and 
endothelial cell adhesion molecule 1; CD31, endo-
thelial cells), and TE-7 (a marker of APFs (5% ± 2%; 
Fig. 1C), indicative of a high purity of hHSC 
cultures.
alD Human HsCs eXHiBit a 
moRe aCtiVateD pHenotype 
CompaReD WitH noRmal 
Human HsCs
Despite hHSC culturing, elevated basal levels of 
TGFβ1 (transforming growth factor beta), Col1a1, 
α-SMA, TIMP1, and LoxL2 (lysyl oxidase homolog 
2) mRNA were detected in ALD hHSCs, compared 
with normal hHSCs, using quantitative real-time PCR 
(Fig. 1D). Stimulation with TGFβ1 (5  ng/mL, 
24  hours) further increased expression of TGFβ1, 
Col1a1, α-SMA, and PAI1 (plasminogen activator 
inhibitor-1) mRNA in ALD hHSCs (compared 
Hepatology CommuniCations, april 2020LIU, ROSENTHAL, ET AL.
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Fig. 1. Primary cultured alcohol-activated hHSCs exhibit a more activated phenotype than normal hHSCs. (A) Donor information: 
donors without underlying liver disease (N1-N4). Donors with ALD (A1-A3) were diagnosed based on liver function, histology, and 
history of alcohol abuse. (B) Human livers (healthy [n = 4] or ALD [n = 3]) were stained for H&E, sirius red, α-SMA, CD68, and 
trichrome. Positive area was calculated as a percentage; representative micrographs are shown (×4 objective). (C) Primary human HSCs 
were immunostained for GFAP, DES, CD31, CD11b, and elastin (TE-7 antibody). (D) Alcohol-activated hHSCs (A1) and normal hHSCs 
(N3) were stimulated ± TGFβ1 (5 ng/mL), SB431542 (10 µM), IL-6 (10 ng/mL), and PDGFβ (10 ng/mL) for 24 hours, and analyzed 
by quantitative real-time PCR (*P < 0.05, **P < 0.01, ***P < 0.001), Student t test, and one-way analysis of variance. Abbreviations: ALT, 
alanine aminotransferase; AST, aspartate aminotransferase; BF, Bright-Field; Ctrl, control.
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with a level higher than in normal hHSCs), and 
this effect was blocked in the presence of the 
TGFβ1 inhibitor SB431542 (10  µM). Expression 
of Col1a1 and α-SMA mRNA was also induced in 
ALD hHSCs in response to interleukin-6 (IL-6; 
10  ng/mL, 24  hours). In turn, PDGFβ (10  ng/mL, 
24  hours) exhibited similar responses in both nor-
mal and ALD hHSCs, as shown by up-regulation 
of the marker of proliferation Ki-67 RNA. Despite 
prolonged culture, primary alcohol-activated hHSCs 
retained an activated phenotype compared with nor-
mal hHSCs.
Rna-seq-BaseD analyses 
iDentiFieD DiFFeRenCes 
in tHe gene-eXpRession 
pRoFiles oF alD Human HsCs 
anD noRmal Human HsCs
Transcriptomes of normal and alcohol-activated 
hHSCs were compared using RNA-Seq and ana-
lyzed using a tiered approach, starting with the most 
stringent analysis of the transcriptome-wide similar-
ities between samples using multidimensional scal-
ing analysis of 12,649 genes expressed in hHSCs 
Fig. 1. Continued.
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(Fig. 2A), and demonstrated that ALD hHSCs 
were separated from normal hHSCs, suggesting that 
the gene-expression profile of ALD hHSCs is sig-
nificantly altered compared with normal hHSCs. 
Differential expression analysis of all expressed genes 
identified 11 genes that were highly and significantly 
up-regulated or down-regulated in ALD hHSCs ver-
sus normal hHSCs, after correcting for multiple tests 
(Benjamini-Hochberg adjusted; P  <  0.3; Fig. 2A). 
Eight genes were up-regulated (ADA2 [adenosine 
deaminase 2], MEX3B [Mex-3 RNA binding family 
member B], STARD5 [StAR-related lipid transfer 
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domain containing 5], OPN3 [opsin 3], TRIM58 
[tripartite motif containing 58], MAN1C1 [manno-
sidase alpha class 1C member 1], BST2 [bone mar-
row stromal cell antigen 2], and ID3 [inhibitor of 
DNA binding 3, HLH protein]), and three genes 
were down-regulated (IGFBP3 [insulin-like growth 
factor binding protein 3], TNFAIP6 [tumor necro-
sis factor alpha induced protein 6], and NTM [neu-
rotrimin]) in ALD hHSCs compared with normal 
hHSCs (Fig. 2A), suggesting that dysregulation of 
these genes discriminates ALD hHSCs from normal 
hHSCs.
Human samples are variable, and other sources of 
variation likely exist in the samples, as hHSCs are 
derived from donors in whom the primary sources 
of variation are associated not only with alcohol con-
sumption but also with other underlying health issues. 
To identify more genes related to ALD, we relaxed 
the differential expression criterion to an unadjusted 
P value of 0.05 and took the top 500 gene results 
to identify genes that best distinguish ALD hHSCs 
from normal hHSCs. We found a strong separation 
between the gene expression in normal and ALD 
hHSCs (Fig. 2B). This indicates that many of the 
nominally significant genes truly differentiate the nor-
mal and diseased states, and that many of our find-
ings will become significant in larger sample sizes. For 
this reason we used the set of 500 most differentially 
expressed genes as the basis of the following analysis. 
The same separation pattern is seen in the 50 most 
up-regulated or down-regulated genes that were most 
differentially expressed between ALD hHSCs and 
normal hHSCs (Fig. 2C). This separation observed at 
all levels of stringency suggests that the phenotype of 
alcohol-activated hHSCs differs from that observed 
in normal hHSCs, despite undergoing culturing on 
plastic dishes.
tHiRty-nine patHWays WeRe 
DysRegulateD in alCoHol-
aCtiVateD Human HsCs (VeRsus 
noRmal Human HsCs)
Functional enrichment analysis of the top 500 most 
differentially expressed genes for significant overlap 
with known biological pathways (using the KEGG 
and REACTOME pathway databases) identified 39 
enriched pathways that were significantly dysregulated 
in alcohol-activated hHSCs (vs. normal hHSCs). (The 
top 15 up-regulated pathways are shown in Fig. 3A.) 
These pathways included genes implicated in the reg-
ulation of fibrogenic responses (extracellular matrix 
[ECM] organization, rheumatoid arthritis pathways), 
TGFβ1 production (hemostasis, platelet degranulation, 
and activation pathways), innate responses (activation 
of toll-like receptor [TLR] signaling; Staph. aureus 
Fig. 2. Eleven most dysregulated genes that best discriminate ALD hHSCs from normal hHSCs. (A) Eleven genes that are significantly 
differentially expressed (red, up-regulated; blue, down-regulated) between ALD and normal hHSCs. (B,C) Heatmap showing the relative 
gene expression between the top 500 (B) or top 50 (C) most differentially expressed genes in normal and ALD hHSCs. The genes 
were grouped by similarity to each other using hierarchical clustering. The Benjamini-Hochberg method for multiple test corrections 
was applied to differentiate the expression results. Eleven genes were changed significantly with the Benjamini-Hochberg method 
(adjusted P <  0.3). Abbreviations: adj.P.Val, multiple-test-corrected P value using the method of Benjamini-Hochberg; AveExpr, 
average expression across all samples; logFC, log fold change in expression between ALD and normal hHSCs; P.Value, P value for 
the comparison. Abbreviations: ADA2, adenosine deaminase 2; AGT, angiotensinogen; APOE, apolipoprotein E; ARHGAP29, rho 
GTPase activating protein 29; BST2, bone marrow stromal cell antigen 2; CCL26, C-C motif chemokine ligand 26; CDCP1, CUB 
domain containing protein 1; CES1, carboxylesterase 1; CLU, clusterin; COL8A1, collagen type VIII alpha 1 chain; CTPS1, CTP 
synthase 1; DCSTAMP, dendrocyte expressed seven transmembrane protein; DGCR6, DiGeorge syndrome critical region gene 6; F2R, 
coagulation factor II thrombin receptor; GDNF, glial cell derived neurotrophic factor; GEM, GTP binding protein overexpressed in 
skeletal muscle; HIST1H1C, H1.2 linker histone, cluster member; HLA-DRA, major histocompatibility complex, class II, DR alpha; 
HLA-F, major histocompatibility complex, class I, F; HS6ST1, heparan sulfate 6-O-sulfotransferase 1; HSPB2, heat shock protein 
family B (small) member 2; ID3, inhibitor of DNA binding 3; IFI27, interferon alpha inducible protein 27; IGFBP3, insulin like 
growth factor binding protein 3; IL13RA2, interleukin 13 receptor subunit alpha 2; MAN1C1, mannosidase alpha class 1C member 1; 
MCOLN1, mucolipin 1; MET, MET proto-oncogene, receptor tyrosine kinase; MEX3B, mex-3 RNA binding family member B; NTM, 
neurotrimin; OLFM1, olfactomedin 1; OMG, oligodendrocyte myelin glycoprotein; OPN3, opsin 3; PAPSS2, 3,-phosphoadenosine 
5,-phosphosulfate synthase 2; PDGFRL, platelet derived growth factor receptor like; PLA2G7, phospholipase A2 group VII; PLK2, polo 
like kinase 2; PTGDS, prostaglandin D2 synthase; RENBP, renin binding protein; SERPINA3, serpin family a member 3; SLC7A8, 
solute carrier family 7 member 8; STARD5, StAR related lipid transfer domain containing 5; TENM2, teneurin transmembrane protein 
2; TGFBI, transforming growth factor beta induced; TGM2, transglutaminase 2; TNFAIP6, tumor necrosis factor-alpha-induced 
protein 6; TRIM58, Tripartite motif containing 58.
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infection, phagosomal and lysosomal pathways), and 
acquired immunity (antigen presentation and cytokine 
signaling pathways). Given the high purity of hHSCs, 
our data suggest that in addition to ECM deposition, 
ALD hHSCs might mediate immune responses (com-
pared with normal hHSCs).
patHWay DysRegulation in 
alD hHsCs CoRRelates WitH 
alCoHoliC liVeR CiRRHosis
Next, we tested whether the pathways detected in 
ALD hHSCs (vs. normal hHSCs) were associated with 
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specific human diseases. Indeed, analysis of a curated 
database of disease-gene associations (DisGeNET, 
http://www.disge net.org) revealed a strong enrichment 
of the top 500 most differentially expressed genes in 
the alcohol-activated hHSCs for human genes related 
to liver cirrhosis, alcoholic and nonalcoholic cirrhosis 
and fibrosis, alcoholic liver damage, chronic alcoholic 
liver disease, liver failure, and liver neoplasms (Fig. 3B).
Analysis of the liver cirrhosis gene set revealed 
that 49 genes from the top 500 most differentially 
expressed between ALD hHSCs (vs. normal hHSCs) 
overlapped with the genes in the liver cirrhosis gene 
set (false discovery rate–adjusted P value = 1.24−6; Fig. 
3C). These 49 genes included NRG1 (neuregulin 1), 
S1PR1 (sphingosine-1-phosphate receptor 1), MT2A 
(metallothionein 2A), PGN (peptidoglycan), MME 
(membrane metalloendopeptidase), NPAS2 (neuro-
nal PAS domain protein 2), IGFBP3, CAV1 (caveolin 
1), SLC4A4 (solute carrier family 4 member 4), and 
RABGAP (Rab GTPase-activating protein), which 
were up-regulated in normal hHSCs, and genes 
PLIN2 (perilipin 2), RPH3AL (rabphilin 3A [without 
C2 domains]), SULT1E1 (sulfotransferase family 1E 
member 1), CD276, RAMP1 (receptor activity mod-
ifying protein 1), and HMOX1 (heme oxygenase 1), 
which were up-regulated in ALD hHSCs. Moreover, 
the up-regulation of liver cirrhosis–associated genes 
(IL18BP, Cxcl16 [C-X-C motif chemokine ligand 
16], CD74, CD53, CSF1R, Ly96 [lymphocyte antigen 
96], TGFβ3, PLEK, MYO1F [myosin IF], MMP9, 
TYROBP, Acp5 [acid phosphatase 5, tartrate resis-
tant], PTPRO [protein tyrosine phosphatase recep-
tor type O], POMC [proopiomelanocortin], GPNMB 
[glycoprotein Nmb], FAM167B [family with sequence 
similarity 167 member B]) was observed in ALD 
hHSCs (A1, from donor with stage 4 liver fibrosis, 
Fig. 3C), suggesting that the expression level of these 
genes might reflect the activation status of ALD 
hHSCs. Moreover, comparison of the alcoholic liver 
cirrhosis and liver cirrhosis gene clusters revealed 
that ALD hHSCs uniquely up-regulated alcohol- 
metabolizing enzyme CYP2E1 (cytochrome P450 
family 2 subfamily E member 1), GPX1 (glutathi-
one peroxidase 1), and APOE (apolipoprotein E), 
and down-regulated vitamin D receptor (Fig. 3D), 
whereas expression of CAV1 and SULT1E1 was 
strongly induced (in comparison with liver cirrhosis).
mouse anD Human HsCs 
eXpRess similaR aCtiVation 
maRKeRs
To translate our findings in humans to mice, the 
gene-expression profiles of ALD hHSCs and mHSCs, 
Fig. 3. Fibrogenic and immune pathways are dysregulated in alcohol-activated hHSCs (compared with normal hHSCs). (A) Functional 
enrichment analysis of the top 500 most differentially expressed genes between ALD and normal hHSCs identified 39 dysregulated 
pathways. The top 15 up-regulated pathways (out of 39) are shown. The significance of the pathway enrichment is shown on the x axis 
(negative log Benjamini-Hochberg–adjusted P value). (B) The top 500 differentially expressed genes demonstrate a significant association 
with curated liver disease gene sets (DisGeNet, http://www.disge net.org/dbinfo). The q-value false discovery rate is the Benjamini-
Hochberg–adjusted P value for the gene-set enrichment. (C,D) Heatmap showing the relative expression between ALD and healthy HSCs 
for genes in the liver cirrhosis experimental DisGeNet gene set (C) or differentially expressed genes in the alcoholic liver cirrhosis DisGeNet 
gene set (compared with the liver cirrhosis experimental DisGeNet gene set). (D). The genes were grouped by similarity to each other 
using hierarchical clustering. Pathway significance and disease gene-set significance was assessed using hypergeometric tests to compare the 
significance of the observed overlap in genes. P values are corrected for multiple testing with the Benjamini-Hochberg method (adjusted 
P < 0.05). Abbreviations: B&H, Benjamini-Hochberg; FDR, false discovery rate. Abbreviations: A2M, alpha-2-macroglobulin; ACP5, 
acid phosphatase 5; AGT, angiotensinogen; ANXA5, annexin A5; APOE, apolipoprotein E; C5AR1, complement C5a receptor 1; CAT, 
catalase; CAV1, caveolin 1; CD14, CD14 molecule; CD276, CD276 molecule; CD53, CD53 molecule; CD74, CD74 molecule; CFD, 
complement factor D; CSF1R, colony stimulating factor 1 receptor; CTSS, cathepsin S; CXCL16, C-X-C motif chemokine ligand 16; 
CYBA, cytochrome b-245 alpha chain; CYP2E1, cytochrome P450 family 2 subfamily E member 1; F2R, coagulation factor II thrombin 
receptor; FAM167B, family with sequence similarity 167 member B; GPNMB, glycoprotein nmb; GPX1, glutathione peroxidase 1; HMOX1, 
heme oxygenase 1; IGFBP3, insulin like growth factor binding protein 3; IL18BP, interleukin 18 binding protein; INMT, indolethylamine 
N-methyltransferase; ITGB2, integrin subunit beta 2; LAPTM5, lysosomal protein transmembrane 5; LCP1, lymphocyte cytosolic protein 
1; LGMN, legumain; LY96, lymphocyte antigen 96; MME, membrane metalloendopeptidase; MMP9, matrix metallopeptidase 9; MT2A, 
metallothionein 2A; MYO1F, myosin IF; NPAS2, neuronal PAS domain protein 2; NRG1, neuregulin 1; PLEK, pleckstrin; PLIN2, 
perilipin 2; POMC, proopiomelanocortin; PTPRO, protein tyrosine phosphatase receptor type O; RABGAP1L, RAB GTPase activating 
protein 1 like; RAMP1, receptor activity modifying protein 1; RGN, regucalcin; RPH3AL, rabphilin 3A like; S1PR1, sphingosine-1-
phosphate receptor 1; SDS, serine dehydratase; SLC4A4, solute carrier family 4 member 4; SOCS2, suppressor of cytokine signaling 2; 
SULT1E1, sulfotransferase family 1E member 1; TGFB3, transforming growth factor beta 3;  TYROBP, TYRO protein tyrosine kinase 
binding protein; UNC93B1, unc-93 homolog B1; VDR, vitamin D receptor; XPNPEP2, X-prolyl  minopeptidase 2.
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activated either by IG alcohol feeding or CCl4, were 
compared (development of liver fibrosis in these 
mice is shown in Supporting Fig. S1). The hHSCs 
and mHSCs showed striking similarities in gene- 
expression profiles. A comparison of ALD hHSCs 
(Fig. 4A) with alcohol-activated and CCl4-activated 
mHSCs (Fig. 4B,C) demonstrated that expression of 
fibrogenic genes (such as Col4a1, Col1a1, TIMP1, Lox, 
and PDGFRβ) was highly conserved among species, 
whereas expression of quiescent markers (particularly 
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LRAT, NGFR1, CYGB, and others) was slightly 
diverged in human versus mouse aHSCs, perhaps 
reflecting that the hHSCs had been cultured.
alD Human HsCs sHaRe moRe 
similaRities WitH alCoHol-
aCtiVateD mouse HsCs tHan 
WitH CCl4-aCtiVateD mouse HsCs
Both IG alcohol feeding and CCl4 induce hepa-
totoxic injury in mice, but the underlying etiology of 
mHSC activation differs between these two models. 
We hypothesized that IG alcohol feeding most closely 
recapitulates ALD in patients, and therefore, alcohol- 
activated hHSCs and mHSCs should share expres-
sion of a specific gene set that distinguishes them from 
CCl4-activated mHSCs. Alcohol-activated hHSCs and 
mHSCs were compared at the level of overall gene 
expression (by measuring the number of shared genes 
among the most highly expressed genes) or differen-
tial gene expression (by comparing three sets of genes 
that discriminate alcohol-activated hHSCs from nor-
mal hHSCs, and alcohol-activated and CCl4-activated 
mHSCs from appropriate control mHSCs).
Of the 500 most differentially expressed genes, 
249 genes overlapped between ALD hHSCs and 
alcohol-activated mHSCs (49.8%, hypergeometric test, 
P  =  1−279), whereas 196 genes were shared between 
ALD hHSCs and CCl4-activated mHSCs (39.2%, 
P = 2−188, not shown). Specifically, of the top 100 most 
differentially expressed genes, 40 genes were simi-
larly expressed in ALD hHSCs and mHSCs (40.0%, 
hypergeometric test, P = 6−70, Fig. 4D), and 29 genes 
overlapped in ALD hHSCs and CCl4-activated 
mHSCs (29.0%, P = 1−45, Fig. 4E). We concluded that 
ALD hHSCs share more similarities with alcohol- 
activated mHSCs than with CCl4-activated mHSCs.
DysRegulateD gene 
ontology teRm/patHWays aRe 
HigHly ConseRVeD BetWeen 
alCoHol-aCtiVateD Human 
HsCs anD mouse HsCs
To identify a specific set of alcohol-induced genes, 
the pathways found to be significantly altered in 
ALD hHSCs (vs. normal hHSCs, such as the 39 
pathways depicted in Fig. 3B) were compared with 
the Gene Ontology (GO) term/pathways in alcohol- 
activated or CCl4-activated mHSCs (identified by 
functional enrichment analysis of the top 500 most 
differentially expressed genes vs. appropriate control 
mHSCs). Of the 39 pathways, only 11 pathways were 
shared between ALD hHSCs and CCl4-activated 
mHSCs, whereas 32 pathways were shared between 
Fig. 4. Expression of activation markers is conserved among ALD hHSCs, alcohol-activated, and CCl4-activated mHSCs. (A-C) 
Heatmap displaying the expression of HSC-specific markers in ALD hHSC (A), alcohol-activated (B), and CCl4-activated mHSCs 
(C). (D,E) Venn diagrams demonstrate the overlapping genes (from the top 100 most highly expressed genes) between alcohol-activated 
hHSCs and mHSCs (D) (P = 6−70) or alcohol-activated hHSCs and CCl4-activated mHSCs (E) (P = 1−45). Genes expressed in both pools 
of overlapping genes are shown in red; unique genes are shown in black. Overlap significance was assessed with the hypergeometric test, to 
compare the observed overlap with what is expected, given the randomly selected gene sets. Abbreviations: ACTA2, actin alpha 2, smooth 
muscle; ACTB, actin beta; ACTG1, actin gamma 1; ADIPOR1, adiponectin receptor 1; ALDOA, aldolase, fructose-bisphosphate A; 
B2M, beta-2-microglobulin; CCDC80, coiled-coil domain containing 80; CD36, CD36 molecule; CD63, CD63 molecule; CFL1, cofilin 
1; COL1A1, collagen type I alpha 1 chain; COL1A2, collagen type I alpha 2 chain; COL3A1, collagen type III alpha 1 chain; COL4A1, 
collagen type IV alpha 1 chain; COL4A2, collagen type IV alpha 2 chain; CTSB, cathepsin B; CTSD, cathepsin D; CYGB, cytoglobin; 
DES, desmin; EF1A1, eukaryotic translation elongation factor 1 alpha 1; EEF1G, eukaryotic translation elongation factor 1 gamma; EEF2, 
eukaryotic translation elongation factor 2; ENG, endoglin; FLNA, filamin A; FN1, fibronectin 1; FSTL1, follistatin like 1; FTH1, ferritin 
heavy chain 1; GFAP, glial fibrillary acidic protein; GNAS, GNAS complex locus; HSPA8, heat shock protein family A (Hsp70) member 8; 
IGFBP7, insulin like growth factor binding protein 7; IL17RA, interleukin 17 receptor A; ITGB1, integrin subunit beta 1; LDHA, lactate 
dehydrogenase A; LGALS1, galectin 1; LOX, lysyl oxidase; LOXL2, lysyl oxidase like 2; LRAT, lecithin retinol acyltransferase; LRP1, 
LDL receptor related protein 1; MCAM, melanoma cell adhesion molecule; MYH9, myosin heavy chain 9; MYL6, myosin light chain 6; 
NGFR, nerve growth factor receptor; NR1D2, nuclear receptor subfamily 1 group D member 2; P4HB, prolyl 4-hydroxylase subunit beta; 
PDGFRB, platelet derived growth factor receptor beta; PKM, pyruvate kinase M1/2; PPARG, peroxisome proliferator activated receptor 
gamma; PSAP, prosaposin; RACK1, receptor for activated C kinase 1; RPL7A, ribosomal protein L7a; RPL10, ribosomal protein L10; 
RPL13A, ribosomal protein L13a; RPL4, ribosomal protein L4; RPLP0, ribosomal protein lateral stalk subunit P0; RPS18, ribosomal 
protein S18; RPS2, ribosomal protein S2; SERPINH1, serpin family H member 1; SPARC, secreted protein acidic and cysteine rich; 
SPP1, secreted phosphoprotein 1; SQSTM1, sequestosome 1; SYNM, synemin; SYP, synaptophysin; TAGLN, transgelin; TGFB, TGFB2 
overlapping transcript 1; TIMP1, TIMP metallopeptidase inhibitor 1; TIMP2, TIMP metallopeptidase inhibitor 2; TMSB4X, thymosin 
beta 4 X-linked; TPM1, tropomyosin 1; TPM4, tropomyosin 4; UBC, ubiquitin C; VIM, vimentin.
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ALD hHSCs and alcohol-activated mHSCs (vs. nor-
mal hHSCs/control mHSCs, Fig. 5A,B). These 32 
pathways were largely up-regulated in both alcohol- 
activated hHSCs/mHSCs (vs. normal HSCs/control 
mHSCs) and were associated with fibrogenesis (11 
pathways), coagulation (6 pathways), inflammation 
(8 pathways), antigen presentation (4 pathways), and 
antibacterial response (3 pathways, Fig. 5C). The 
magnitude of dysregulation was stronger in alcohol- 
activated mHSCs than in ALD hHSCs, likely because 
of the greater heterogeneity in human samples. Hence, 
the significant overlap in biological processes pointed 
toward a strong consistency in the effect of alcohol- 
induced liver injury in humans and mice, further sup-
porting our conclusion that the IG model of alcohol 
feeding in mice is suitable to study ALD.
alCoHol-aCtiVateD Human 
HsCs/mouse HsCs sHaReD 
eXpRession oF 35 alCoHol-
inDuCeD genes (VeRsus CCl4-inJuReD mouse HsCs)
We searched for the genes that can distinguish alco-
hol-activated hHSCs/mHSCs from HSCs activated by 
other etiologies. To identify genes uniquely expressed 
only in alcohol-activated hHSCs/mHSCs, the 500 
genes most differentially expressed in ALD hHSCs (vs. 
normal hHSCs), alcohol-activated, and CCl4-activated 
mHSCs (vs. appropriate control mHSCs) were com-
pared. From this comparison, we identified the overlap-
ping genes that were shared among pools. Thirty-three 
genes were commonly dysregulated in ALD hHSCs and 
CCl4-activated mHSCs (P = 0.002, Fig. 6A). However, 
of these 33, only 14 genes were dysregulated in the 
same direction (including down-regulation of IGFBP3 
and up-regulation of Spp1 and TGFβ3), indicating that 
functional pathways differ in ALD hHSCs and CCl4-
induced mHSCs.
In contrast, 44 genes were commonly dysregulated 
in alcohol-activated hHSCs and mHSCs (Fig. 6B, 
P  =  3.9−7), with 35 genes being dysregulated in the 
same direction (including Trem2 [triggering recep-
tor expressed on myeloid cells 2], Tyrobp, PLEK, 
LAPTM5, CD74, CTSS, ITGB2, and CSFR1 [col-
ony stimulating factor receptor 1]). Interestingly, the 
genes that are traditionally associated with HSC acti-
vation (such as Col1a1, TIMP1, and TGFβ) were not 
included in this pool, with the exception of Spp1 and 
Emilin (elastin microfibril interface), suggesting that 
these 35 genes might be uniquely induced in alcohol- 
activated hHSCs/mHSCs.
alCoHol-speCiFiC Human 
HsC/mouse HsC genes aRe 
linKeD to FiBRogenesis 
anD Regulation oF immune 
Responses
Using pathway analysis, functional properties of 35 
alcohol-associated genes were accessed (Fig. 6C) and 
associated with fibrogenesis (e.g., extracellular struc-
ture organization, actin cytoskeleton organization, 
platelet degranulation, glycosaminoglycan biosynthesis, 
cell morphogenesis, lung development) and immune 
responses (e.g., defense response, cytokine-mediated sig-
naling pathway, myeloid/leukocyte differentiation, pro-
liferation, migration). Specifically, some of these genes 
were linked by the GO annotations to fibrosis (FSTL3 
[follistatin like 3], EMILIN2, HS6ST1 [heparan sulfate 
6-O-sulfotransferase 1], GPC1 [glypican 1], PLA2g7 
[phospholipase A2 group VII], FMOD [fibromodulin], 
MMP9, MAFB [MAF BZIP transcription factor B], 
IRF7 [interferon regulatory factor 7], CD9, Spp1, and 
LCP1 [lymphocyte cytosolic protein 1]), angiogenesis 
(VEGFC [vascular endothelial growth factor C]), anti-
gen presentation (CD74 and CTSS), innate immunity 
(CSF1R, CD14, CARD9 [caspase recruitment domain 
family member 9], TYROBP, and TREM2), phagocyto-
sis (CYBA [cytochromeb-245 light chain], MSR1 [mac-
rophage scavenger receptor types I and II], LAPTM5, 
BST2, and RIMS3 [regulating synaptic membrane exo-
cytosis 3]), and reactive oxygen species (AOX1 [alde-
hyde oxidase 1] and GLRX [glutaredoxin]).
a minimal ComBination 
oF 14 genes iDentiFieD tHe 
signatuRe genes oF alCoHol-
aCtiVateD Human HsCs/mouse 
HsCs
The interconnection among these 35 genes 
was further defined using a cross-species protein– 
protein interaction network (https ://string-db.org/cgi/
network; Fig. 6D). There were 40 connections among 
these 35 genes, greatly exceeding the expected num-
ber of four connections (P  <  1−16, permutation test), 
indicating that the identified alcohol-specific hHSC/
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Fig. 5. Pathways are shared between alcohol-activated hHSCs and mHSCs. (A,B) Pathways commonly dysregulated in alcohol-activated 
hHSCs and mHSCs (A) in alcohol-activated hHSCs and CCl4-activated mHSCs (B), shown as Venn diagrams. (Pathways that were 
significantly enriched in the top 500 most differentially expressed genes between alcohol-activated and control HSCs were identified using 
the hypergeometric test–adjusted P < 0.05). (C) Thirty-two pathways shared between alcohol-activated hHSCs and mHSCs. The top 
500 differentially expressed genes were used for pathway analysis. Abbreviations: Average logFC human, average log fold change between 
ALD and normal hHSCs for genes in the pathway; average logFC mouse, alc IG, average log fold change between alcohol-activated and 
quiescent mHSCs (from IG alcohol-fed mice) for genes in the pathway; adjusted P value, human, significance of the pathway enrichment 
in human, adjusted for multiple tests using the method of Benjamini-Hochberg; adjusted P value, mouse, alc IG, significance of the 
pathway enrichment in mouse intragastric model, adjusted for multiple tests using the method of Benjamini-Hochberg.
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mHSC genes are representative of common underly-
ing pathways and known functional processes.
A number of genes (such as AOX1, MSR1, PLA2G7, 
MAFB, CD9, CARD9, ADARB1 [adenosine deaminase 
RNA specific B1], FMOD, GLRX, RIMS3, EMILIN2, 
and ID1 [inhibitor of DNA binding 1, HLH protein]) 
showed no known connections to other genes (with 
the network of 35 genes), and despite high expression, 
were not a part of the network. Therefore, we narrowed 
the network of 35 genes by including the most highly 
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connected genes (≥2 connections in the network), and 
identified 14 genes (CD14, CSF1R, TYROBP, PLEK, 
LAPTM5, CD53, CYBA, MMP9, CD14, ITGB2, CTSS, 
Spp1, and IRF7) that formed the core of a provisionary 
protein network. Based on the central position within 
the network and high ties to other proteins, 3 of the 14 
core genes (ITGB2, TYROBP, and CTSS) appeared to 
play a regulatory role within the network, meaning that 
they may have the largest effect on connection between 
genes/pathways. Overall, CSF1R, PLEK, LAPTM5, 
CD74, CD53, MMP9, CD14, CTSS, TYROBP, 
and ITGB2 were identified as “signature genes” of 
alcohol-activated hHSCs/mHSCs (Fig. 7A), which are 
functionally linked to fibrogenic responses (osteoclast 
differentiation, ECM, and collagen binding pathways) 
and immune responses (TLR cascade and signaling, 
exocytosis, lysosome, and adaptive and innate immunity 
pathways) (Fig. 7B). Similar results were obtained using 
another cohort of normal and ALD human HSCs (cul-
tured to P0; see Supporting Fig. S2 and Supporting 
Information text). Our data indicate that high expres-
sion of CD74, TYROBP, TREM2, and CTSS is associ-
ated with ALD hHSCs (Fig. 7C,D). These genes alone, 
or in combination with others, may become therapeutic 
targets, or serve as a readout for successful treatment of 
experimental models of ALD. Expression of selected 
genes was confirmed in alcohol-activated mHSCs (iso-
lated from IG alcohol-fed mice; Supporting Fig. S3) 
and hHSCs (n = 3) (vs. normal hHSCs, n = 3) isolated 
from different donors (A4-A6 and N5-N7, cultured 
to P1; Fig. 7D), suggesting that expression of identi-
fied genes distinguishes alcohol-activated human HSCs 
from normal HSCs despite culture activation.
Discussion
We examined the transcriptomic differences 
between primary hHSCs isolated from ALD livers or 
normal livers. Despite the heterogeneity of the ALD 
and normal donors, primary cultured ALD hHSCs 
remained transcriptionally distinct from normal 
hHSCs, suggesting that hHSCs maintain specific epi-
genetic characteristics in culture that determine their 
phenotype (quiescent or activated). Then we com-
pared hHSCs and mHSCs, and identified that pri-
mary alcohol-activated mHSCs, freshly isolated from 
livers of IG alcohol-fed mice, most closely recapitulate 
the gene-expression profile of primary cultured ALD 
hHSCs. Moreover, we identified the genes that are 
Fig. 6. Expression of 35 genes distinguishes alcohol-activated hHSCs and mHSCs from CCl4-activated mHSCs. (A) Scatterplot shows 
33 overlapping genes from the top 500 genes in ALD (vs. normal) hHSCs and CCl4-activated (vs. quiescent) mHSCs (hypergeometric 
test, P = 0.002). Fourteen genes were dysregulated in the same direction. Genes located in the pink square are up-regulated, and those in 
the blue square are down-regulated, in both hHSCs and mHSCs. (B) Scatterplot shows 44 overlapping genes from the top 500 genes 
ALD (vs. normal) hHSCs and alcohol-activated (vs. quiescent) mHSCs (P = 3.9−7). Thirty-five genes dysregulated in the same direction 
are shown in the pink (up-regulated) and blue (down-regulated) squares in both alcohol-activated hHSCs and mHSCs. (C) GO term/
pathway analysis of 35 genes overlapping between alcohol-activated hHSCs/mHSCs. (D) Thirty-five genes were grouped in a cross-
species protein–protein interaction network (https/ /string-db.org). Significantly more connections were found among the genes than 
expected by chance (P < 1−16, permutation test). Abbreviations: ABI3BP, ABI family member 3 binding protein; ADARB1, adenosine 
deaminase RNA specific B1; AOX1, aldehyde oxidase 1; BOC, BOC cell adhesion associated; BST2, bone marrow stromal cell antigen 2; 
CARD9, caspase recruitment domain family member 9; CAV1, caveolin 1; CD14, CD14 molecule; CD44, CD44 molecule; CD52, CD52 
molecule; CD53, CD53 molecule; CD74, CD74 molecule; CD84, CD84 molecule; CD9, CD9 molecule; COL8A1, collagen type VIII 
alpha 1 chain; CPXM1, carboxypeptidase X, M14 family member 1; CSF1R, colony stimulating factor 1 receptor; CTHRC1, collagen triple 
helix repeat containing 1; CTSS, cathepsin S; CYBA, cytochrome b-245 alpha chain; DCLK1, doublecortin like kinase 1; DMPK, DM1 
protein kinase; EMILIN2, elastin microfibril interfacer 2; FGF2, fibroblast growth factor 2; FMOD, fibromodulin; FSTL3, follistatin like 
3; GEM, GTP binding protein overexpressed in skeletal muscle; GLRX, glutaredoxin; GPC1, glypican 1; HAS2, hyaluronan synthase 2; 
HIST1H1C, H1.2 linker histone, cluster member; HS6ST1, heparan sulfate 6-O-sulfotransferase 1; HSPA1A, heat shock protein family 
A (Hsp70) member 1A; ID1, inhibitor of DNA binding 1; IGFBP3, insulin like growth factor binding protein 3; IL11, interleukin 11; 
IL1R2, interleukin 1 receptor type 2; INHBA, inhibin subunit beta A; IRF7, interferon regulatory factor 7; ITGB2, integrin subunit 
beta 2; KLF10, kruppel like factor 10; LAPTM5, lysosomal protein transmembrane 5; LCP1, lymphocyte cytosolic protein 1; MAFB, 
MAF bZIP transcription factor B; MMP9, matrix metallopeptidase 9; MSR1, macrophage scavenger receptor 1; NCAM1, neural cell 
adhesion molecule 1; PGM5, phosphoglucomutase 5; PLA2G7, phospholipase A2 group VII; PLCB2, phospholipase C beta 2; PLCB4, 
phospholipase C beta 4; PLEK, pleckstrin; PLXNC1, plexin C1; RASGRP3, RAS guanyl releasing protein 3; RGS14, regulator of G 
protein signaling 14; RIMS3, regulating synaptic membrane exocytosis 3; RSPO3, R-spondin 3; SEPT5, Septin 5; SERINC2, serine 
incorporator 2; SOX17, SRY-box transcription factor 17; SPP1, secreted phosphoprotein 1; TGFB3, transforming growth factor beta 3; 
TIMP3, TIMP metallopeptidase inhibitor 3; TMEM140, transmembrane protein 140; TNC, tenascin C; TREM2, triggering receptor 
expressed on myeloid cells 2; TYROBP, TYRO protein tyrosine kinase binding protein; VCAN, versican; VDR, vitamin D receptor; 
VEGFC, vascular endothelial growth factor C; WT1, WT1 transcription factor.
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similarly and uniquely up-regulated in alcohol-activated 
hHSCs and mHSCs, suggesting that these genes may 
serve as targets for antifibrotic therapy in ALD.
Because isolation of primary hHSCs is challeng-
ing, most studies rely on immortal human HSC cell 
lines, such as LX2 or hTERT, which retain some but 
Fig. 7. Fourteen genes were identified as the signature genes of alcohol-activated hHSCs/mHSCs. (A) Fourteen genes with 2 or fewer 
connections within the network were identified as signature genes of alcohol-activated hHSCs/mHSCs. The P value and Benjamini-
Hochberg–adjusted P value of alcohol-activated (vs. normal) hHSCs are shown. (B) Functional enrichment analysis identified pathways 
associated with these 14 genes (six pathways are shown) and were grouped in a cross-species protein–protein interaction network 
(https/ /string-db.org). The pathways shown are significantly enriched for these 14 genes with Benjamini-Hochberg–adjusted P < 0.05. 
(C) Expression of selected genes was analyzed by quantitative real-time PCR in normal hHSCs (n = 3, N5, N6, N7) and ALD hHSCs 
(n = 3, A3, A4, A5) isolated from a different set of donors (*P < 0.05, **P < 0.01, ***P < 0.001; Student t test and one-way analysis of 
variance). (D) Donor information: N5-N7, donors without underlying liver disease; A4-A6, donors with ALD who were diagnosed based 
on liver function, histology, and history of alcohol abuse. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase. 
Abbreviations: CD14, CD14 molecule; CD53, CD53 molecule; CD74, CD74 molecule; CSF1R, Colony stimulating factor 1 receptor; 
CTSS, Cathepsin S; CYBA, Cytochrome b-245 alpha chain; IRF7, Interferon regulatory factor 7; ITGB2, Integrin subunit beta 2; 
LAPTM5, Lysosomal protein transmembrane 5; MMP9, Matrix metallopeptidase 9; PLEK, Pleckstrin; SPP1, Secreted phosphoprotein 
1; TREM2, Teneurin transmembrane protein 2; TYROBP, TYRO protein tyrosine kinase binding protein.
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not all features of hHSCs. Primary hHSCs can be 
isolated from resected livers by cell outgrowth from 
liver slices. In addition to hHSCs, this technique 
might produce myofibroblasts through epithelial-to- 
mesenchymal transition of plastic activated hepatic 
cells. Alternatively, hHSCs are purified using pronase/ 
collagenase digestion and gradient centrifugation, 
which is based on the buoyancy of the vitamin-A 
lipid droplets in HSCs. The number and viability of 
purified hHSCs can be diminished by the small vol-
ume of resected livers and by tissue hypoxia. Human 
HSCs isolated from patients with ALD (or NASH) 
are often contaminated with fatty hepatocytes, thereby 
precluding gene-expression profiling of the freshly 
isolated hHSC cultures, unless single-cell RNA-Seq 
is performed. The whole-liver single-cell RNA-Seq 
effectively identified genes that are characteristic for 
activated hHSCs, but the depth of sequencing failed 
to identify unique and disease-specific genes. Single-
cell RNA analysis of human livers recently revealed 
novel markers of human HSCs.(12) Although the 
single-cell analysis identified genes that distinguish 
HSCs from other hepatic cell types, we identified 
some of the same genes in our study (including CTSS, 
CD74, CYBA, ID1, FSTL3, and FMOD). Moreover, 
our study identified genes that differentiate ALD 
hHSCs from normal hHSCs.
Here we analyzed the transcriptome of ALD and 
normal hHSCs from donor livers declined for trans-
plantation. These livers were preserved (perfused with 
Wisconsin solution [ViaSpan; Bristol Meyers Squibb, 
New York, NY] and kept  less than 24 hours on ice to 
reduce tissue hypoxia). Human HSCs were isolated 
from the whole liver lobe to ensure high quality and 
heterogeneity of the hHSC population. The hHSCs 
were cultured to eliminate contaminating pronase- 
injured hepatocytes, and to expand the hHSC popula-
tion. Although expression of some genes (LOX, TIMP1, 
and others) was induced in cultured ALD and normal 
hHSCs, expression of other genes was not affected by 
Fig. 7. Continued.
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plastic activation, and clearly discriminated between 
ALD from normal hHSCs. This gene set was used to 
identify the similarities between cultured ALD hHSCs 
and alcohol-activated mHSCs. Notably, purification of 
mHSCs from alcohol-damaged livers has similar prob-
lems as described for ALD hHSCs, but can be over-
come by cell sorting of freshly isolated mHSCs for 
collagen α1(I)-GFP+ reporter(9) and ultraviolet-excited 
vitamin A fluorescence, which eliminates contaminat-
ing steatotic hepatocytes.(6) Overall, we identified genes 
that highly overlap in cultured ALD hHSCs (and not 
changed by plastic activation) and primary freshly iso-
lated alcohol-activated mHSCs.
A tiered stringency approach was used to interro-
gate the gene-expression profiles of ALD and normal 
hHSCs, starting with the most stringent analysis of 
genes significantly changed, accounting for multiple 
testing, and then expanding the list of differentially 
expressed genes by decreasing the stringency of the 
inclusion criteria to include the top 500 most dif-
ferentially expressed genes. Expression of highly 
up-regulated genes in ALD hHSCs (ADA2, MEX3B, 
TRIM58 and MAN1C1) or down-regulated genes 
(IGFBP3 and NTM) discriminate between the alcohol- 
activated and normal hHSCs, accounting for multiple 
test corrections.
IGFBP3 and NTM were implicated in the main-
tenance of the qHSC phenotype. Consistent with 
previous observations,(13-17) expression of IGFBP3 
and NTM were strongly down-regulated in alco-
hol-activated hHSCs (vs. normal hHSCs). In turn, 
ADA2, a growth factor for endothelial cells and a 
promoter of differentiation of M2 macrophages,(18) 
was highly induced in ALD HSCs. Although this 
is the first observation of the role of ADA2 in HSC 
biology, our findings extend the positive correla-
tion between activation of HSCs and stimulation 
of liver sinusoidal endothelial cells. Previous studies 
have demonstrated that activated HSCs produce the 
angiogenic factors vascular endothelial factor(19) and 
angiopoietin 1.(20)
Functional enrichment analysis of a large pool of 
the top differentially expressed genes reveals signif-
icant up-regulation of 39 pathways in ALD HSCs, 
including cytokine signaling, platelet activation, and 
ECM organization, all of which are known to be 
up-regulated in mouse models of fibrotic liver dis-
ease,(21) as well as significant associations with known 
liver-disease gene sets. Comparison of the alcoholic 
cirrhosis versus cirrhosis gene sets revealed that 
CYP2E1, CD14, and CAV1 were strongly induced in 
alcohol-activated hHSCs. Similarly, alcohol-activated 
HSCs up-regulate CYP2E1 (an alcohol metabolizing 
enzyme) in response to chronic liver injury. This effect 
is associated with activation of TLR4/CD14 signal-
ing in aHSCs and Kupffer cells,(8) whereas expression 
of CAV1, implicated in lipid droplet formation in 
hHSCs and intracellular trafficking,(22,23) was reduced 
in ALD hHSCs compared with normal hHSCs.
Previous studies have focused primarily on char-
acterization of either mouse or human HSCs.(21,24) 
Using high-confidence mHSC data to extract rele-
vant signal from noisy hHSC data, we identified the 
most differentially and significantly expressed genes 
in both hHSCs and mHSCs, indicating that the IG 
model of alcohol feeding most closely recapitulates 
ALD hHSCs. This approach was fully untargeted, so 
the results are an unbiased summary of the genes that 
are commonly dysregulated by alcohol across species 
and interconnected in known protein–protein inter-
action networks. Similar approaches have been used 
previously,(25) but to our knowledge, this is the first 
systematic analysis of the common protein interaction 
networks common for alcohol-activated hHSCs and 
mHSCs, showing how the identified genes are func-
tionally connected.
Specifically, a general concordance among the 
expression of known HSC signature genes was 
observed in hHSCs and mHSCs. Of the genes typi-
cally associated with activated or quiescent hHSC and 
mHSC phenotypes, expression of LRAT was notably 
suppressed in cultured ALD hHSCs compared with 
mHSCs and can be attributed to a true organismal 
difference at the level of gene expression or meta-
bolic processes. Dietary differences may also contrib-
ute differential LRAT gene expression in hHSCs and 
mHSC.(26)
Significant similarities were detected between 
ALD hHSCs and alcohol-activated mHSCs (vs. 
CCl4-activated mHSCs). Of the 35 genes that were 
uniquely up-regulated in alcohol-activated hHSCs/
mHSCs, CSF1R, PLEK, LAPTM5, CD74, CD53, 
MMP9, CD14, CTSS, TYROBP, and ITGB2 were 
identified as signature genes of alcohol-activated 
hHSCs/mHSCs, and their functions were linked to 
fibrogenic/ECM-associated pathways and immuno- 
regulatory pathways in myofibroblasts.(27-29) By study-
ing these pathways, we can target genes downstream 
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of potential HSC activators and inhibit the response 
to injury. The ECM is a component of all mamma-
lian tissues, consisting of the proteins collagen, elas-
tin, and fibronectin.(30) Secretion of abundant ECM 
proteins is a hallmark of fibrosis, and as expected, 
the ECM organization pathway was significantly up- 
regulated in both alcohol-activated mHSCs and 
hHSCs. Our study implicates alcohol-activated hHSCs 
and mHSCs in the mediation of fibrosis-associated 
immune processes, and in particular activation of the 
innate immune system,(8) whereas some of the identi-
fied pathways are novel for HSC biology. Thus, the role 
of TYROBP, TREM2, and ITGB2 genes in regulation 
of adaptive/innate immune responses has recently 
been proposed. TYROBP/TREM2 binding was 
shown to suppresses the release of pro-inflammatory 
cytokines, and activate phagocytosis of apoptotic 
cells by myeloid/microglial cells.(31,32) Moreover, 
expression of CD74,(33) CTSS,(34) and LAPTM5 was 
linked in MHC class I endolysosomal antigen pre-
sentation. Although aHSCs were shown to mediate 
antigen presentation and phagocytosis,(35,36) these 
functions appear to be highly amplified in alcohol- 
activated hHSCs/mHSCs. These signals might reg-
ulate ALD hHSC/mHSC activation, motility, and 
the cross talk between alcohol-damaged hepatocytes 
and Kupffer cells/macrophages. Remarkably, a com-
bination of five to six of these genes was associated 
with astroglial sensome in Alzheimer’s disease,(37) 
amyotrophic lateral sclerosis,(38) and osteoclasts dif-
ferentiation,(39) outlining the functional commonali-
ties of these genes for disease manifestation in various 
tissues.
This study provides evidence that alcohol-activated 
hHSCs and mHSCs share expression of specific 
alcohol-induced signature genes, suggesting that IG 
alcohol-fed mice serve as the best preclinical experi-
mental model of alcohol-induced liver fibrosis in mice 
to study human ALD.
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